ERBB2 and familial pancreatic carcinoma: Fascinatingly, numerous current studies have displayed that emodin might synergistically progress the anti-cancer efficiency of conventional chemotherapeutic drugs, such as cisplatin, etoposide, paclitaxel, and gemcitabine in pancreatic cancer [33], HER-2/neu-overexpressing lung cancer, and malignant melanoma without additional toxic effects [34,35,36,37].